{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:12:09Z","timestamp":1787807529399,"version":"build-2784847793"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02846-7","type":"journal-article","created":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T14:13:04Z","timestamp":1751119984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["MicroRNA-driven organ-specific metastasis in triple-negative breast cancer: biogenesis, mechanisms, and therapeutic approaches"],"prefix":"10.1007","volume":"42","author":[{"given":"Deepshikha","family":"Rathore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sweny","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanaya","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandani","family":"Dharwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirali","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jigna","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6029-6515","authenticated-orcid":false,"given":"Heena V.","family":"Dave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,28]]},"reference":[{"issue":"17","key":"2846_CR1","doi-asserted-by":"publisher","first-page":"15349","DOI":"10.1007\/s00432-023-05313-w","volume":"149","author":"R Hammad","year":"2023","unstructured":"Hammad R, et al. Monocytes subsets altered distribution and dysregulated plasma hsa-miR-21-5p and hsa-miR-155-5p in HCV-linked liver cirrhosis progression to hepatocellular carcinoma. J Cancer Res Clin Oncol. 2023;149(17):15349\u201364. https:\/\/doi.org\/10.1007\/s00432-023-05313-w.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2846_CR2","doi-asserted-by":"publisher","first-page":"138773","DOI":"10.1016\/j.ijbiomac.2024.138773","volume":"289","author":"NM Hamdy","year":"2025","unstructured":"Hamdy NM, et al. Insights into the genetic and epigenetic mechanisms governing X-chromosome-linked-miRNAs expression in cancer; a step-toward ncRNA precision. Int J Biol Macromol. 2025;289:138773. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.138773.","journal-title":"Int J Biol Macromol"},{"key":"2846_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/genes13030481","author":"S Tian","year":"2022","unstructured":"Tian S, Wang J, Zhang F, Wang D. Comparative analysis of microRNA binding site distribution and microRNA-mediated gene expression repression of oncogenes and tumor suppressor genes. Genes (Basel). 2022. https:\/\/doi.org\/10.3390\/genes13030481.","journal-title":"Genes (Basel)"},{"issue":"1","key":"2846_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/1465-9921-11-159","volume":"11","author":"T Tomankova","year":"2010","unstructured":"Tomankova T, Petrek M, Kriegova E. Involvement of microRNAs in physiological and pathological processes in the lung. Respir Res. 2010;11(1):159. https:\/\/doi.org\/10.1186\/1465-9921-11-159.","journal-title":"Respir Res"},{"issue":"1","key":"2846_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12885-020-07731-2","volume":"21","author":"AF Evangelista","year":"2021","unstructured":"Evangelista AF, Oliveira RJ, Silva VAO, Vieira RADC, Reis RM, Marques MMC. Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer. BMC Cancer. 2021;21(1):76. https:\/\/doi.org\/10.1186\/s12885-020-07731-2.","journal-title":"BMC Cancer"},{"issue":"6","key":"2846_CR6","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/onc.2012.636","volume":"33","author":"W Kong","year":"2014","unstructured":"Kong W, et al. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene. 2014;33(6):679\u201389. https:\/\/doi.org\/10.1038\/onc.2012.636.","journal-title":"Oncogene"},{"key":"2846_CR7","doi-asserted-by":"publisher","first-page":"155651","DOI":"10.1016\/j.prp.2024.155651","volume":"263","author":"NM Hamdy","year":"2024","unstructured":"Hamdy NM, et al. In silico analysis and comprehensive review of circular-RNA regulatory roles in breast diseases; a step-toward non-coding RNA precision. Pathol Res Pract. 2024;263:155651. https:\/\/doi.org\/10.1016\/j.prp.2024.155651.","journal-title":"Pathol Res Pract"},{"key":"2846_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/genes14071375","author":"A Chakrabortty","year":"2023","unstructured":"Chakrabortty A, Patton DJ, Smith BF, Agarwal P. miRNAs: potential as biomarkers and therapeutic targets for cancer. Genes (Basel). 2023. https:\/\/doi.org\/10.3390\/genes14071375.","journal-title":"Genes (Basel)"},{"key":"2846_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11070652","author":"C Damaskos","year":"2021","unstructured":"Damaskos C, et al. Investigational drug treatments for triple-negative breast cancer. J Pers Med. 2021. https:\/\/doi.org\/10.3390\/jpm11070652.","journal-title":"J Pers Med"},{"key":"2846_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073904","author":"Y-F Chiang","year":"2024","unstructured":"Chiang Y-F, et al. Hinokitiol inhibits breast cancer cells in vitro stemness-progression and self-renewal with apoptosis and autophagy modulation via the CD44\/Nanog\/SOX2\/Oct4 pathway. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25073904.","journal-title":"Int J Mol Sci"},{"key":"2846_CR11","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1200\/GO.20.00054","volume":"6","author":"A Kulkarni","year":"2020","unstructured":"Kulkarni A, Kelkar DA, Parikh N, Shashidhara LS, Koppiker CB, Kulkarni M. Meta-analysis of prevalence of triple-negative breast cancer and its clinical features at incidence in indian patients with breast cancer. JCO Glob Oncol. 2020;6:1052\u201362. https:\/\/doi.org\/10.1200\/GO.20.00054.","journal-title":"JCO Glob Oncol"},{"key":"2846_CR12","doi-asserted-by":"publisher","first-page":"7054134","DOI":"10.1155\/2021\/7054134","volume":"2021","author":"C Ameh-Mensah","year":"2021","unstructured":"Ameh-Mensah C, Duduyemi BM, Bedu-Addo K, Atta Manu E, Opoku F, Titiloye N. The analysis of bcl-2 in association with p53 and Ki-67 in triple negative breast cancer and other molecular subtypes in Ghana. J Oncol. 2021;2021:7054134. https:\/\/doi.org\/10.1155\/2021\/7054134.","journal-title":"J Oncol"},{"key":"2846_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032969","author":"NS van den Ende","year":"2023","unstructured":"van den Ende NS, Nguyen AH, Jager A, Kok M, Debets R, van Deurzen CHM. Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: a systematic review. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24032969.","journal-title":"Int J Mol Sci"},{"key":"2846_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010321","author":"L Li","year":"2023","unstructured":"Li L, Zhang F, Liu Z, Fan Z. Immunotherapy for triple-negative breast cancer: combination strategies to improve outcome. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15010321.","journal-title":"Cancers (Basel)"},{"key":"2846_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101791","author":"M Kesireddy","year":"2024","unstructured":"Kesireddy M, et al. Overall survival and prognostic factors in metastatic triple-negative breast cancer: a national cancer database analysis. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16101791.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2846_CR16","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41598-021-04316-2","volume":"12","author":"J-Y Hsu","year":"2022","unstructured":"Hsu J-Y, Chang C-J, Cheng J-S. Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer. Sci Rep. 2022;12(1):729. https:\/\/doi.org\/10.1038\/s41598-021-04316-2.","journal-title":"Sci Rep"},{"issue":"1","key":"2846_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):1\u201313. https:\/\/doi.org\/10.1186\/s13058-020-01296-5.","journal-title":"Breast Cancer Res"},{"key":"2846_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-018-0047-0","author":"W Chen","year":"2018","unstructured":"Chen W, Hoffmann AD, Liu H, Liu X. \u201cOrganotropism: new insights into molecular mechanisms of breast cancer metastasis.\u201d npj Precis Oncol. 2018. https:\/\/doi.org\/10.1038\/s41698-018-0047-0.","journal-title":"npj Precis Oncol"},{"issue":"11","key":"2846_CR19","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1002\/ijc.26031","volume":"128","author":"RR Langley","year":"2011","unstructured":"Langley RR, Fidler IJ. The seed and soil hypothesis revisited\u2013the role of tumor-stroma interactions in metastasis to different organs. Int J cancer. 2011;128(11):2527\u201335. https:\/\/doi.org\/10.1002\/ijc.26031.","journal-title":"Int J cancer"},{"issue":"1","key":"2846_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12964-021-00787-y","volume":"19","author":"G Berumen S\u00e1nchez","year":"2021","unstructured":"Berumen S\u00e1nchez G, Bunn KE, Pua HH, Rafat M. Extracellular vesicles: mediators of intercellular communication in tissue injury and disease. Cell Commun Signal. 2021;19(1):104. https:\/\/doi.org\/10.1186\/s12964-021-00787-y.","journal-title":"Cell Commun Signal"},{"key":"2846_CR21","doi-asserted-by":"publisher","first-page":"703640","DOI":"10.3389\/fmolb.2021.703640","volume":"8","author":"X Yang","year":"2021","unstructured":"Yang X, et al. The key role of exosomes on the pre-metastatic Niche formation in tumors. Front Mol Biosci. 2021;8:703640. https:\/\/doi.org\/10.3389\/fmolb.2021.703640.","journal-title":"Front Mol Biosci"},{"issue":"3","key":"2846_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nrclinonc.2016.144","volume":"14","author":"M Mohme","year":"2017","unstructured":"Mohme M, Riethdorf S, Pantel K. Circulating and disseminated tumour cells \u2014 mechanisms of immune surveillance and escape. Nat Rev Clin Oncol. 2017;14(3):155\u201367. https:\/\/doi.org\/10.1038\/nrclinonc.2016.144.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"2846_CR23","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.5858\/arpa.2022-0464-RA","volume":"147","author":"H Sun","year":"2023","unstructured":"Sun H, Ding Q, Sahin AA. Immunohistochemistry in the diagnosis and classification of breast tumors. Arch Pathol Lab Med. 2023;147(10):1119\u201332. https:\/\/doi.org\/10.5858\/arpa.2022-0464-RA.","journal-title":"Arch Pathol Lab Med"},{"issue":"Suppl 6","key":"2846_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/annonc\/mds190","volume":"23","author":"F Penault-Llorca","year":"2012","unstructured":"Penault-Llorca F, Viale G. Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective. Ann Oncol Off J Eur Soc Med Oncol. 2012;23(Suppl 6):19\u201322. https:\/\/doi.org\/10.1093\/annonc\/mds190.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2846_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57010062","author":"SA Dass","year":"2021","unstructured":"Dass SA, et al. Triple negative breast cancer: a review of present and future diagnostic modalities. Medicina. 2021. https:\/\/doi.org\/10.3390\/medicina57010062.","journal-title":"Medicina"},{"issue":"Suppl 2","key":"2846_CR26","doi-asserted-by":"publisher","first-page":"e000504","DOI":"10.1136\/esmoopen-2019-000504","volume":"4","author":"R Caparica","year":"2019","unstructured":"Caparica R, Lambertini M, de Azambuja E. How I treat metastatic triple-negative breast cancer. ESMO Open. 2019;4(Suppl 2):e000504. https:\/\/doi.org\/10.1136\/esmoopen-2019-000504.","journal-title":"ESMO Open"},{"issue":"3","key":"2846_CR27","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00262-020-02736-z","volume":"70","author":"D Kwapisz","year":"2021","unstructured":"Kwapisz D. Pembrolizumab and atezolizumab in triple-negative breast cancer. Cancer Immunol Immunother. 2021;70(3):607\u201317. https:\/\/doi.org\/10.1007\/s00262-020-02736-z.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2846_CR28","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s12672-025-02227-6","volume":"16","author":"HM Emara","year":"2025","unstructured":"Emara HM, Allam NK, Youness RA. A comprehensive review on targeted therapies for triple negative breast cancer: an evidence-based treatment guideline. Discov Oncol. 2025;16(1):547. https:\/\/doi.org\/10.1007\/s12672-025-02227-6.","journal-title":"Discov Oncol"},{"key":"2846_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11206021","author":"S Li","year":"2022","unstructured":"Li S, Bao C, Huang L, Wei J-F. Current therapeutic strategies for metastatic triple-negative breast cancer: from pharmacists\u2019 perspective. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11206021.","journal-title":"J Clin Med"},{"issue":"7","key":"2846_CR30","doi-asserted-by":"publisher","first-page":"7951","DOI":"10.1002\/cam4.5575","volume":"12","author":"Y Yang","year":"2023","unstructured":"Yang Y, et al. Prognosis prediction and risk factors for triple-negative breast cancer patients with brain metastasis: A population-based study. Cancer Med. 2023;12(7):7951\u201361. https:\/\/doi.org\/10.1002\/cam4.5575.","journal-title":"Cancer Med"},{"issue":"1","key":"2846_CR31","doi-asserted-by":"publisher","first-page":"11177","DOI":"10.1038\/s41598-019-47581-y","volume":"9","author":"V Tubita","year":"2019","unstructured":"Tubita V, et al. Effect of immunosuppression in miRNAs from extracellular vesicles of colorectal cancer and their influence on the pre-metastatic niche. Sci Rep. 2019;9(1):11177. https:\/\/doi.org\/10.1038\/s41598-019-47581-y.","journal-title":"Sci Rep"},{"issue":"September","key":"2846_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcell.2021.733627","volume":"9","author":"Q Dong","year":"2021","unstructured":"Dong Q, Liu X, Cheng K, Sheng J, Kong J, Liu T. Pre-metastatic niche formation in different organs induced by tumor extracellular vesicles. Front Cell Dev Biol. 2021;9(September):1\u20138. https:\/\/doi.org\/10.3389\/fcell.2021.733627.","journal-title":"Front Cell Dev Biol"},{"key":"2846_CR33","doi-asserted-by":"publisher","first-page":"581007","DOI":"10.3389\/fonc.2020.581007","volume":"10","author":"T Annese","year":"2020","unstructured":"Annese T, Tamma R, De Giorgis M, Ribatti D. microRNAs biogenesis, functions and role in tumor angiogenesis. Front Oncol. 2020;10:581007. https:\/\/doi.org\/10.3389\/fonc.2020.581007.","journal-title":"Front Oncol"},{"issue":"17","key":"2846_CR34","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1101\/gad.1953310","volume":"24","author":"MMW Chong","year":"2010","unstructured":"Chong MMW, Zhang G, Cheloufi S, Neubert TA, Hannon GJ, Littman DR. Canonical and alternate functions of the microRNA biogenesis machinery. Genes Dev. 2010;24(17):1951\u201360. https:\/\/doi.org\/10.1101\/gad.1953310.","journal-title":"Genes Dev"},{"issue":"3","key":"2846_CR35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.tig.2018.12.005","volume":"35","author":"LB Chipman","year":"2019","unstructured":"Chipman LB, Pasquinelli AE. miRNA targeting: growing beyond the seed. Trends Genet. 2019;35(3):215\u201322. https:\/\/doi.org\/10.1016\/j.tig.2018.12.005.","journal-title":"Trends Genet"},{"key":"2846_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/cells8111465","author":"CJ Stavast","year":"2019","unstructured":"Stavast CJ, Erkeland SJ. The non-canonical aspects of microRNAs: many roads to gene regulation. Cells. 2019. https:\/\/doi.org\/10.3390\/cells8111465.","journal-title":"Cells"},{"issue":"2","key":"2846_CR37","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.celrep.2018.12.054","volume":"26","author":"X Bofill-De Ros","year":"2019","unstructured":"Bofill-De Ros X, et al. Structural differences between Pri-miRNA paralogs promote alternative drosha cleavage and expand target repertoires. Cell Rep. 2019;26(2):447-459.e4. https:\/\/doi.org\/10.1016\/j.celrep.2018.12.054.","journal-title":"Cell Rep"},{"issue":"2","key":"2846_CR38","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1261\/rna.5167604","volume":"10","author":"MT Bohnsack","year":"2004","unstructured":"Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA. 2004;10(2):185\u201391. https:\/\/doi.org\/10.1261\/rna.5167604.","journal-title":"RNA"},{"key":"2846_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00402","author":"J O\u2019Brien","year":"2018","unstructured":"O\u2019Brien J, Hayder H, Zayed Y, Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne). 2018. https:\/\/doi.org\/10.3389\/fendo.2018.00402.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2846_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.00592","author":"A Pereira","year":"2019","unstructured":"Pereira A, et al. miRNome reveals new insights into the molecular biology of field cancerization in gastric cancer. Front Genet. 2019. https:\/\/doi.org\/10.3389\/fgene.2019.00592.","journal-title":"Front Genet"},{"key":"2846_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ncrna9050058","author":"S Eldash","year":"2023","unstructured":"Eldash S, Sanad EF, Nada D, Hamdy NM. The intergenic type LncRNA (LINC RNA) faces in cancer with in silico scope and a directed lens to LINC00511: a step toward ncRNA precision. Non-coding RNA. 2023. https:\/\/doi.org\/10.3390\/ncrna9050058.","journal-title":"Non-coding RNA"},{"issue":"1","key":"2846_CR42","doi-asserted-by":"publisher","first-page":"13694","DOI":"10.1038\/ncomms13694","volume":"7","author":"M Fareh","year":"2016","unstructured":"Fareh M, Yeom K-H, Haagsma AC, Chauhan S, Heo I, Joo C. TRBP ensures efficient Dicer processing of precursor microRNA in RNA-crowded environments. Nat Commun. 2016;7(1):13694. https:\/\/doi.org\/10.1038\/ncomms13694.","journal-title":"Nat Commun"},{"issue":"3","key":"2846_CR43","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/PPO.0b013e318250c001","volume":"18","author":"MV Iorio","year":"2012","unstructured":"Iorio MV, Croce CM. Causes and consequences of microRNA dysregulation. Cancer J. 2012;18(3):215\u201322. https:\/\/doi.org\/10.1097\/PPO.0b013e318250c001.","journal-title":"Cancer J"},{"issue":"3","key":"2846_CR44","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd.2016.246","volume":"16","author":"R Rupaimoole","year":"2017","unstructured":"Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203\u201322. https:\/\/doi.org\/10.1038\/nrd.2016.246.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"2846_CR45","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/bcr2484","volume":"12","author":"E O\u2019Day","year":"2010","unstructured":"O\u2019Day E, Lal A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res. 2010;12(2):201. https:\/\/doi.org\/10.1186\/bcr2484.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"2846_CR46","first-page":"98","volume":"8","author":"S Paget","year":"1989","unstructured":"Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989;8(2):98\u2013101.","journal-title":"Cancer Metastasis Rev"},{"issue":"11","key":"2846_CR47","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/ncponc0342","volume":"2","author":"G Gasparini","year":"2005","unstructured":"Gasparini G, Longo R, Toi M, Ferrara N. Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol. 2005;2(11):562\u201377. https:\/\/doi.org\/10.1038\/ncponc0342.","journal-title":"Nat Clin Pract Oncol"},{"issue":"6","key":"2846_CR48","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.trecan.2016.05.006","volume":"2","author":"EB Rankin","year":"2016","unstructured":"Rankin EB, Nam JM, Giaccia AJ. Hypoxia: signaling the metastatic cascade. Trends in Cancer. 2016;2(6):295\u2013304. https:\/\/doi.org\/10.1016\/j.trecan.2016.05.006.","journal-title":"Trends in Cancer"},{"key":"2846_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00031","author":"C Neophytou","year":"2018","unstructured":"Neophytou C, Boutsikos P, Papageorgis P. Molecular mechanisms and emerging therapeutic targets of triple-negative breast cancer metastasis. Front Oncol. 2018. https:\/\/doi.org\/10.3389\/fonc.2018.00031.","journal-title":"Front Oncol"},{"key":"2846_CR50","doi-asserted-by":"publisher","first-page":"108522","DOI":"10.1016\/j.pharmthera.2023.108522","volume":"250","author":"SU Khan","year":"2023","unstructured":"Khan SU, Fatima K, Malik F, Kalkavan H, Wani A. Cancer metastasis: molecular mechanisms and clinical perspectives. Pharmacol Ther. 2023;250:108522. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108522.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"2846_CR51","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374\u2013403. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.016.","journal-title":"Cancer Cell"},{"issue":"5","key":"2846_CR52","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.1002\/mco2.350","volume":"4","author":"K Liao","year":"2023","unstructured":"Liao K, et al. The role of platelets in the regulation of tumor growth and metastasis: the mechanisms and targeted therapy. MedComm. 2023;4(5):e350. https:\/\/doi.org\/10.1002\/mco2.350.","journal-title":"MedComm"},{"issue":"1","key":"2846_CR53","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41392-025-02148-4","volume":"10","author":"Y Li","year":"2025","unstructured":"Li Y, et al. Invasion and metastasis in cancer: molecular insights and therapeutic targets. Signal Transduct Target Ther. 2025;10(1):57. https:\/\/doi.org\/10.1038\/s41392-025-02148-4.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"2846_CR54","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1101\/gad.277681.116","volume":"30","author":"T Celi\u00e0-Terrassa","year":"2016","unstructured":"Celi\u00e0-Terrassa T, Kang Y. Distinctive properties of metastasis-initiating cells. Genes Dev. 2016;30(8):892\u2013908. https:\/\/doi.org\/10.1101\/gad.277681.116.","journal-title":"Genes Dev"},{"issue":"7","key":"2846_CR55","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41588-020-0628-z","volume":"52","author":"Z Hu","year":"2020","unstructured":"Hu Z, Li Z, Ma Z, Curtis C. Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases. Nat Genet. 2020;52(7):701\u20138. https:\/\/doi.org\/10.1038\/s41588-020-0628-z.","journal-title":"Nat Genet"},{"issue":"1","key":"2846_CR56","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.bbcan.2019.06.002","volume":"1872","author":"M Ale\u010dkovi\u0107","year":"2019","unstructured":"Ale\u010dkovi\u0107 M, McAllister SS, Polyak K. Metastasis as a systemic disease: molecular insights and clinical implications. Biochim Biophys Acta - Rev Cancer. 2019;1872(1):89\u2013102. https:\/\/doi.org\/10.1016\/j.bbcan.2019.06.002.","journal-title":"Biochim Biophys Acta - Rev Cancer"},{"issue":"11","key":"2846_CR57","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1096\/fba.2021-00079","volume":"3","author":"S Ghoroghi","year":"2021","unstructured":"Ghoroghi S, Mary B, Asokan N, Goetz JG, Hyenne V. Tumor extracellular vesicles drive metastasis (it\u2019s a long way from home). FASEB bioAdvances. 2021;3(11):930\u201343. https:\/\/doi.org\/10.1096\/fba.2021-00079.","journal-title":"FASEB bioAdvances"},{"key":"2846_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2018.02.013","volume":"188","author":"MP Bebelman","year":"2018","unstructured":"Bebelman MP, Smit MJ, Pegtel DM, Baglio SR. Biogenesis and function of extracellular vesicles in cancer. Pharmacol Ther. 2018;188:1\u201311. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.02.013.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"2846_CR59","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41392-020-0134-x","volume":"5","author":"J Fares","year":"2020","unstructured":"Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther. 2020;5(1):28. https:\/\/doi.org\/10.1038\/s41392-020-0134-x.","journal-title":"Signal Transduct Target Ther"},{"key":"2846_CR60","doi-asserted-by":"publisher","first-page":"104076","DOI":"10.1016\/j.compbiomed.2020.104076","volume":"127","author":"S Banerjee","year":"2020","unstructured":"Banerjee S, Kalyani Yabalooru SR, Karunagaran D. Identification of mRNA and non-coding RNA hubs using network analysis in organ tropism regulated triple negative breast cancer metastasis. Comput Biol Med. 2020;127:104076. https:\/\/doi.org\/10.1016\/j.compbiomed.2020.104076.","journal-title":"Comput Biol Med"},{"key":"2846_CR61","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2013_038","author":"L Tseng","year":"2013","unstructured":"Tseng L, et al. Distant metastasis in triple-negative breast cancer. Neoplasma. 2013. https:\/\/doi.org\/10.4149\/neo_2013_038.","journal-title":"Neoplasma"},{"issue":"3","key":"2846_CR62","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1152\/physrev.00012.2019","volume":"101","author":"P Cl\u00e9zardin","year":"2021","unstructured":"Cl\u00e9zardin P, et al. Bone metastasis: mechanisms, therapies, and biomarkers. Physiol Rev. 2021;101(3):797\u2013855. https:\/\/doi.org\/10.1152\/physrev.00012.2019.","journal-title":"Physiol Rev"},{"issue":"1","key":"2846_CR63","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck N, et al. Breast cancer. Nat Rev Dis Prim. 2019;5(1):66. https:\/\/doi.org\/10.1038\/s41572-019-0111-2.","journal-title":"Nat Rev Dis Prim"},{"issue":"2","key":"2846_CR64","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00223-017-0365-1","volume":"102","author":"N Rucci","year":"2018","unstructured":"Rucci N, Teti A. Osteomimicry: how the seed grows in the soil. Calcif Tissue Int. 2018;102(2):131\u201340. https:\/\/doi.org\/10.1007\/s00223-017-0365-1.","journal-title":"Calcif Tissue Int"},{"key":"2846_CR65","doi-asserted-by":"publisher","DOI":"10.3791\/61313","author":"BE III Hildreth","year":"2020","unstructured":"III Hildreth BE, Palmer C, Allen MJ. Modeling primary bone tumors and bone metastasis with solid tumor graft implantation into bone. J Vis Exp. 2020. https:\/\/doi.org\/10.3791\/61313.","journal-title":"J Vis Exp"},{"issue":"3","key":"2846_CR66","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40610-018-0099-5","volume":"4","author":"A Cappariello","year":"2018","unstructured":"Cappariello A, Capulli M. The vicious cycle of breast cancer-induced bone metastases, a complex biological and therapeutic target. Curr Mol Biol Reports. 2018;4(3):123\u201331. https:\/\/doi.org\/10.1007\/s40610-018-0099-5.","journal-title":"Curr Mol Biol Reports"},{"issue":"1","key":"2846_CR67","doi-asserted-by":"publisher","first-page":"321","DOI":"10.4081\/oncol.2017.321","volume":"11","author":"F Macedo","year":"2017","unstructured":"Macedo F, et al. Bone metastases: an overview. Oncol Rev. 2017;11(1):321. https:\/\/doi.org\/10.4081\/oncol.2017.321.","journal-title":"Oncol Rev"},{"key":"2846_CR68","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.phrs.2019.04.030","volume":"144","author":"X Pang","year":"2019","unstructured":"Pang X, Gong K, Zhang X, Wu S, Cui Y, Qian B-Z. Osteopontin as a multifaceted driver of bone metastasis and drug resistance. Pharmacol Res. 2019;144:235\u201344. https:\/\/doi.org\/10.1016\/j.phrs.2019.04.030.","journal-title":"Pharmacol Res"},{"issue":"1","key":"2846_CR69","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4161\/cbt.7.1.5163","volume":"7","author":"M Akhtari","year":"2008","unstructured":"Akhtari M, Mansuri J, Newman KA, Guise TM, Seth P. Biology of breast cancer bone metastasis. Cancer Biol Ther. 2008;7(1):3\u20139. https:\/\/doi.org\/10.4161\/cbt.7.1.5163.","journal-title":"Cancer Biol Ther"},{"issue":"46","key":"2846_CR70","doi-asserted-by":"publisher","first-page":"75571","DOI":"10.18632\/oncotarget.12289","volume":"7","author":"I Holen","year":"2016","unstructured":"Holen I, et al. IL-1 drives breast cancer growth and bone metastasis in vivo. Oncotarget. 2016;7(46):75571\u201384. https:\/\/doi.org\/10.18632\/oncotarget.12289.","journal-title":"Oncotarget"},{"key":"2846_CR71","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/bonekey.2012.96","volume":"1","author":"JT Buijs","year":"2012","unstructured":"Buijs JT, Stayrook KR, Guise TA. The role of TGF-\u03b2 in bone metastasis: novel therapeutic perspectives. Bonekey Rep. 2012;1:96. https:\/\/doi.org\/10.1038\/bonekey.2012.96.","journal-title":"Bonekey Rep"},{"issue":"12","key":"2846_CR72","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1158\/1078-0432.CCR-18-2697","volume":"25","author":"G Rieunier","year":"2019","unstructured":"Rieunier G, Wu X, Macaulay VM, Lee AV, Weyer-Czernilofsky U, Bogenrieder T. Bad to the bone: the role of the insulin-like growth factor axis in osseous metastasis. Clin Cancer Res. 2019;25(12):3479\u201385. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2697.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2846_CR73","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1158\/1078-0432.306.11.1","volume":"11","author":"DC Lev","year":"2005","unstructured":"Lev DC, et al. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. Clin Cancer Res. 2005;11(1):306\u201314. https:\/\/doi.org\/10.1158\/1078-0432.306.11.1.","journal-title":"Clin Cancer Res"},{"key":"2846_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00076","author":"X Wu","year":"2020","unstructured":"Wu X, Li F, Dang L, Liang C, Lu A, Zhang G. RANKL\/RANK system-based mechanism for breast cancer bone metastasis and related therapeutic strategies. Front Cell Dev Biol. 2020. https:\/\/doi.org\/10.3389\/fcell.2020.00076.","journal-title":"Front Cell Dev Biol"},{"issue":"9","key":"2846_CR75","doi-asserted-by":"publisher","first-page":"841","DOI":"10.5312\/wjo.v15.i9.841","volume":"15","author":"A Hoveidaei","year":"2024","unstructured":"Hoveidaei A, Karimi M, Khalafi V, Fazeli P, Hoveidaei AH. Impacts of radiation therapy on quality of life and pain relief in patients with bone metastases. World J Orthop. 2024;15(9):841\u20139. https:\/\/doi.org\/10.5312\/wjo.v15.i9.841.","journal-title":"World J Orthop"},{"issue":"5","key":"2846_CR76","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.3390\/curroncol28050290","volume":"28","author":"S Tsukamoto","year":"2021","unstructured":"Tsukamoto S, et al. Current overview of treatment for metastatic bone disease. Curr Oncol. 2021;28(5):3347\u201372. https:\/\/doi.org\/10.3390\/curroncol28050290.","journal-title":"Curr Oncol"},{"issue":"2","key":"2846_CR77","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.clon.2020.11.028","volume":"33","author":"I Murray","year":"2021","unstructured":"Murray I, Du Y. Systemic radiotherapy of bone metastases with radionuclides. Clin Oncol. 2021;33(2):98\u2013105. https:\/\/doi.org\/10.1016\/j.clon.2020.11.028.","journal-title":"Clin Oncol"},{"key":"2846_CR78","doi-asserted-by":"publisher","first-page":"1133828","DOI":"10.3389\/fonc.2023.1133828","volume":"13","author":"J Lu","year":"2023","unstructured":"Lu J, Hu D, Zhang Y, Ma C, Shen L, Shuai B. Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials. Front Oncol. 2023;13:1133828. https:\/\/doi.org\/10.3389\/fonc.2023.1133828.","journal-title":"Front Oncol"},{"issue":"1","key":"2846_CR79","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.trecan.2015.07.009","volume":"1","author":"AC Obenauf","year":"2015","unstructured":"Obenauf AC, Massagu\u00e9 J. Surviving at a distance: organ-specific metastasis. Trends in Cancer. 2015;1(1):76\u201391. https:\/\/doi.org\/10.1016\/j.trecan.2015.07.009.","journal-title":"Trends in Cancer"},{"key":"2846_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/BCTT.S274514","volume":"14","author":"A Kadamkulam Syriac","year":"2022","unstructured":"Kadamkulam Syriac A, Nandu NS, Leone JP. \u201cCentral nervous system metastases from triple-negative breast cancer: current treatments and future prospective.\u201d Breast cancer (Dove Med Press). 2022;14:1\u201313. https:\/\/doi.org\/10.2147\/BCTT.S274514.","journal-title":"Breast cancer (Dove Med Press)"},{"issue":"1","key":"2846_CR81","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12987-020-00230-3","volume":"17","author":"H Kadry","year":"2020","unstructured":"Kadry H, Noorani B, Cucullo L. A blood\u2013brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS. 2020;17(1):69. https:\/\/doi.org\/10.1186\/s12987-020-00230-3.","journal-title":"Fluids Barriers CNS"},{"key":"2846_CR82","doi-asserted-by":"publisher","first-page":"589","DOI":"10.2147\/OTT.S293685","volume":"14","author":"Y Lv","year":"2021","unstructured":"Lv Y, Ma X, Du Y, Feng J. Understanding patterns of brain metastasis in triple-negative breast cancer and exploring potential therapeutic targets. Onco Targets Ther. 2021;14:589\u2013607. https:\/\/doi.org\/10.2147\/OTT.S293685.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"2846_CR83","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3390\/ijms14011383","volume":"14","author":"I Wilhelm","year":"2013","unstructured":"Wilhelm I, Moln\u00e1r J, Fazakas C, Hask\u00f3 J, Krizbai IA. Role of the blood-brain barrier in the formation of brain metastases. Int J Mol Sci. 2013;14(1):1383\u2013411. https:\/\/doi.org\/10.3390\/ijms14011383.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2846_CR84","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.trecan.2018.01.003","volume":"4","author":"M Valiente","year":"2018","unstructured":"Valiente M, et al. The evolving landscape of brain metastasis. Trends in Cancer. 2018;4(3):176\u201396. https:\/\/doi.org\/10.1016\/j.trecan.2018.01.003.","journal-title":"Trends in Cancer"},{"issue":"11","key":"2846_CR85","doi-asserted-by":"publisher","first-page":"E1450","DOI":"10.21037\/jtd.2016.11.11","volume":"8","author":"W Dai","year":"2016","unstructured":"Dai W, et al. Orchestration of the crosstalk between astrocytes and cancer cells affects the treatment and prognosis of lung cancer sufferers with brain metastasis. J Thorac Dis. 2016;8(11):E1450\u20134. https:\/\/doi.org\/10.21037\/jtd.2016.11.11.","journal-title":"J Thorac Dis"},{"issue":"7576","key":"2846_CR86","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature15376","volume":"527","author":"L Zhang","year":"2015","unstructured":"Zhang L, et al. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature. 2015;527(7576):100\u20134. https:\/\/doi.org\/10.1038\/nature15376.","journal-title":"Nature"},{"issue":"5","key":"2846_CR87","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.cell.2014.01.040","volume":"156","author":"M Valiente","year":"2014","unstructured":"Valiente M, et al. Serpins promote cancer cell survival and vascular Co-option in brain metastasis. Cell. 2014;156(5):1002\u201316. https:\/\/doi.org\/10.1016\/j.cell.2014.01.040.","journal-title":"Cell"},{"issue":"30","key":"2846_CR88","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1200\/JCO.2015.60.9503","volume":"33","author":"X Lin","year":"2015","unstructured":"Lin X, DeAngelis LM. Treatment of brain metastases. J Clin Oncol. 2015;33(30):3475\u201384. https:\/\/doi.org\/10.1200\/JCO.2015.60.9503.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2846_CR89","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41571-019-0320-3","volume":"17","author":"JH Suh","year":"2020","unstructured":"Suh JH, Kotecha R, Chao ST, Ahluwalia MS, Sahgal A, Chang EL. Current approaches to the management of brain metastases. Nat Rev Clin Oncol. 2020;17(5):279\u201399. https:\/\/doi.org\/10.1038\/s41571-019-0320-3.","journal-title":"Nat Rev Clin Oncol"},{"key":"2846_CR90","doi-asserted-by":"publisher","first-page":"111883","DOI":"10.1016\/j.biopha.2021.111883","volume":"141","author":"R Yang","year":"2021","unstructured":"Yang R, et al. Ruyiping extract reduces lung metastasis in triple negative breast cancer by regulating macrophage polarization. Biomed Pharmacother. 2021;141:111883. https:\/\/doi.org\/10.1016\/j.biopha.2021.111883.","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"2846_CR91","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1080\/15384047.2018.1456599","volume":"19","author":"L Jin","year":"2018","unstructured":"Jin L, Han B, Siegel E, Cui Y, Giuliano A, Cui X. Breast cancer lung metastasis: molecular biology and therapeutic implications. Cancer Biol Ther. 2018;19(10):858\u201368. https:\/\/doi.org\/10.1080\/15384047.2018.1456599.","journal-title":"Cancer Biol Ther"},{"key":"2846_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11071010","author":"GM Stella","year":"2019","unstructured":"Stella GM, Kolling S, Benvenuti S, Bortolotto C. Lung-seeking metastases. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11071010.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2846_CR93","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrm1835","volume":"7","author":"JP Thiery","year":"2006","unstructured":"Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131\u201342. https:\/\/doi.org\/10.1038\/nrm1835.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"2846_CR94","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1084\/jem.193.6.727","volume":"193","author":"EY Lin","year":"2001","unstructured":"Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001;193(6):727\u201340. https:\/\/doi.org\/10.1084\/jem.193.6.727.","journal-title":"J Exp Med"},{"issue":"1","key":"2846_CR95","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","volume":"120","author":"P Berraondo","year":"2019","unstructured":"Berraondo P, et al. Cytokines in clinical cancer immunotherapy. Br J Cancer. 2019;120(1):6\u201315. https:\/\/doi.org\/10.1038\/s41416-018-0328-y.","journal-title":"Br J Cancer"},{"issue":"1","key":"2846_CR96","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3390\/biomedicines13010164","volume":"13","author":"LA Ghenciu","year":"2025","unstructured":"Ghenciu LA, Grigoras ML, Rosu LM, Bolintineanu SL, Sima L, Cretu O. Differentiating Liver Metastases from Primary Liver Cancer: A Retrospective Study of Imaging and Pathological Features in Patients with Histopathological Confirmation. Biomedicines. 2025;13(1):164 https:\/\/doi.org\/10.3390\/biomedicines13010164","journal-title":"Biomedicines"},{"key":"2846_CR97","doi-asserted-by":"publisher","first-page":"153303381876449","DOI":"10.1177\/1533033818764497","volume":"17","author":"C Zhang","year":"2018","unstructured":"Zhang C, et al. TGF\u03b21 promotes breast cancer local invasion and liver metastasis by increasing the CD44(high)\/CD24(\u2013) subpopulation. Technol Cancer Res Treat. 2018;17:1533033818764497. https:\/\/doi.org\/10.1177\/1533033818764497.","journal-title":"Technol Cancer Res Treat"},{"key":"2846_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1043771","author":"C Liu","year":"2022","unstructured":"Liu C, et al. Breast cancer liver metastasis: pathogenesis and clinical implications. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.1043771.","journal-title":"Front Oncol"},{"issue":"2","key":"2846_CR99","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1096\/fj.201700629R","volume":"32","author":"K Binnemars-Postma","year":"2018","unstructured":"Binnemars-Postma K, Bansal R, Storm G, Prakash J. Targeting the Stat6 pathway in tumor-associated macrophages reduces tumor growth and metastatic niche formation in breast cancer. FASEB J Off Publ Fed Am Soc Exp Biol. 2018;32(2):969\u201378. https:\/\/doi.org\/10.1096\/fj.201700629R.","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"2846_CR100","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.ijbiomac.2018.11.089","volume":"123","author":"L Xie","year":"2019","unstructured":"Xie L, Yang Y, Meng J, Wen T, Liu J, Xu H. Cationic polysaccharide spermine-pullulan drives tumor associated macrophage towards M1 phenotype to inhibit tumor progression. Int J Biol Macromol. 2019;123:1012\u20139. https:\/\/doi.org\/10.1016\/j.ijbiomac.2018.11.089.","journal-title":"Int J Biol Macromol"},{"issue":"6","key":"2846_CR101","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jhep.2014.08.025","volume":"61","author":"GK Wilson","year":"2014","unstructured":"Wilson GK, Tennant DA, McKeating JA. Hypoxia inducible factors in liver disease and hepatocellular carcinoma: current understanding and future directions. J Hepatol. 2014;61(6):1397\u2013406. https:\/\/doi.org\/10.1016\/j.jhep.2014.08.025.","journal-title":"J Hepatol"},{"key":"2846_CR102","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.cellimm.2018.03.010","volume":"330","author":"J Keirsse","year":"2018","unstructured":"Keirsse J, Van Damme H, Geeraerts X, Beschin A, Raes G, Van Ginderachter JA. The role of hepatic macrophages in liver metastasis. Cell Immunol. 2018;330:202\u201315. https:\/\/doi.org\/10.1016\/j.cellimm.2018.03.010.","journal-title":"Cell Immunol"},{"key":"2846_CR103","doi-asserted-by":"publisher","first-page":"112824","DOI":"10.1016\/j.biopha.2022.112824","volume":"149","author":"H Liu","year":"2022","unstructured":"Liu H, et al. Potential molecular mechanisms and clinical progress in liver metastasis of breast cancer. Biomed Pharmacother. 2022;149:112824. https:\/\/doi.org\/10.1016\/j.biopha.2022.112824.","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"2846_CR104","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/nrd1580","volume":"3","author":"JM Yingling","year":"2004","unstructured":"Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-\u03b2 signalling inhibitors for cancer therapy. Nat Rev Drug Discov. 2004;3(12):1011\u201322. https:\/\/doi.org\/10.1038\/nrd1580.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"2846_CR105","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10585-021-10080-4","volume":"38","author":"NS Rashid","year":"2021","unstructured":"Rashid NS, Grible JM, Clevenger CV, Harrell JC. Breast cancer liver metastasis: current and future treatment approaches. Clin Exp Metastasis. 2021;38(3):263\u201377. https:\/\/doi.org\/10.1007\/s10585-021-10080-4.","journal-title":"Clin Exp Metastasis"},{"issue":"10","key":"2846_CR106","doi-asserted-by":"publisher","first-page":"e23156","DOI":"10.1002\/jbt.23156","volume":"36","author":"F Lv","year":"2022","unstructured":"Lv F, Qin J, Kong S, Pan L, Ding R. MicroRNA-506 ameliorates breast cancer-induced osteolytic bone metastasis via the NFATc-1 signaling pathway. J Biochem Mol Toxicol. 2022;36(10):e23156. https:\/\/doi.org\/10.1002\/jbt.23156.","journal-title":"J Biochem Mol Toxicol"},{"key":"2846_CR107","doi-asserted-by":"publisher","first-page":"115139","DOI":"10.1016\/j.bone.2019.115139","volume":"130","author":"X Zhang","year":"2020","unstructured":"Zhang X, et al. MicroRNA-429 inhibits bone metastasis in breast cancer by regulating CrkL and MMP-9. Bone. 2020;130:115139. https:\/\/doi.org\/10.1016\/j.bone.2019.115139.","journal-title":"Bone"},{"key":"2846_CR108","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1515\/med-2017-0023","volume":"12","author":"L Wang","year":"2017","unstructured":"Wang L, Li M, Zhou Y, Zhao Y. MicroRNA Let-7g directly targets forkhead box C2 (FOXC2) to modulate bone metastasis in breast cancer. Open Med (Warsaw, Poland). 2017;12:157\u201362. https:\/\/doi.org\/10.1515\/med-2017-0023.","journal-title":"Open Med (Warsaw, Poland)"},{"key":"2846_CR109","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2021.5277","author":"K Kitayama","year":"2021","unstructured":"Kitayama K, et al. Regulatory roles of miRNAs 16, 133a, and 223 on osteoclastic bone destruction caused by breast cancer metastasis. Int J Oncol. 2021. https:\/\/doi.org\/10.3892\/ijo.2021.5277.","journal-title":"Int J Oncol"},{"issue":"48","key":"2846_CR110","doi-asserted-by":"publisher","first-page":"79032","DOI":"10.18632\/oncotarget.12593","volume":"7","author":"H Taipaleenm\u00e4ki","year":"2016","unstructured":"Taipaleenm\u00e4ki H, et al. Antagonizing miR-218-5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells. Oncotarget. 2016;7(48):79032\u201346. https:\/\/doi.org\/10.18632\/oncotarget.12593.","journal-title":"Oncotarget"},{"issue":"7","key":"2846_CR111","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1158\/0008-5472.CAN-14-1026","volume":"75","author":"H Taipaleenm\u00e4ki","year":"2015","unstructured":"Taipaleenm\u00e4ki H, et al. Targeting of Runx2 by miR-135 and miR-203 impairs progression of breast cancer and metastatic bone disease. Cancer Res. 2015;75(7):1433\u201344. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-1026.","journal-title":"Cancer Res"},{"issue":"2","key":"2846_CR112","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11060-023-04541-x","volume":"166","author":"K Hudson","year":"2024","unstructured":"Hudson K, et al. The role of microRNAs in brain metastasis. J Neurooncol. 2024;166(2):231\u201341. https:\/\/doi.org\/10.1007\/s11060-023-04541-x.","journal-title":"J Neurooncol"},{"issue":"3","key":"2846_CR113","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1158\/0008-5472.CAN-10-1910","volume":"71","author":"L Zhang","year":"2011","unstructured":"Zhang L, Sullivan PS, Goodman JC, Gunaratne PH, Marchetti D. MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase. Cancer Res. 2011;71(3):645\u201354. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-1910.","journal-title":"Cancer Res"},{"issue":"37","key":"2846_CR114","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1038\/onc.2014.412","volume":"34","author":"F Xing","year":"2015","unstructured":"Xing F, et al. miR-509 suppresses brain metastasis of breast cancer cells by modulating RhoC and TNF-\u03b1. Oncogene. 2015;34(37):4890\u2013900. https:\/\/doi.org\/10.1038\/onc.2014.412.","journal-title":"Oncogene"},{"key":"2846_CR115","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2147\/BCTT.S372083","volume":"14","author":"D Hammash","year":"2022","unstructured":"Hammash D, et al. \u201cmiR-623 targets metalloproteinase-1 and attenuates extravasation of brain metastatic triple-negative breast cancer cells.\u201d Breast Cancer (Dove Med Press). 2022;14:187\u201398. https:\/\/doi.org\/10.2147\/BCTT.S372083.","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"9","key":"2846_CR116","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1038\/s41388-021-01654-3","volume":"40","author":"JK Pan","year":"2021","unstructured":"Pan JK, et al. MiR-211 determines brain metastasis specificity through SOX11\/NGN2 axis in triple-negative breast cancer. Oncogene. 2021;40(9):1737\u201351. https:\/\/doi.org\/10.1038\/s41388-021-01654-3.","journal-title":"Oncogene"},{"issue":"3","key":"2846_CR117","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s10549-021-06255-y","volume":"187","author":"R Harati","year":"2021","unstructured":"Harati R, Mabondzo A, Tlili A, Khoder G, Mahfood M, Hamoudi R. Combinatorial targeting of microRNA-26b and microRNA-101 exerts a synergistic inhibition on cyclooxygenase-2 in brain metastatic triple-negative breast cancer cells. Breast Cancer Res Treat. 2021;187(3):695\u2013713. https:\/\/doi.org\/10.1007\/s10549-021-06255-y.","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"2846_CR118","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1080\/15548627.2017.1360466","volume":"13","author":"N Kaverina","year":"2017","unstructured":"Kaverina N, et al. Astrocytes promote progression of breast cancer metastases to the brain via a KISS1-mediated autophagy. Autophagy. 2017;13(11):1905\u201323. https:\/\/doi.org\/10.1080\/15548627.2017.1360466.","journal-title":"Autophagy"},{"issue":"1","key":"2846_CR119","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13058-017-0865-y","volume":"19","author":"J Wang","year":"2017","unstructured":"Wang J, et al. miR-629\u20133p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer. Breast Cancer Res. 2017;19(1):72. https:\/\/doi.org\/10.1186\/s13058-017-0865-y.","journal-title":"Breast Cancer Res"},{"issue":"34","key":"2846_CR120","doi-asserted-by":"publisher","first-page":"4662","DOI":"10.1038\/s41388-018-0293-1","volume":"37","author":"P-S Wang","year":"2018","unstructured":"Wang P-S, et al. A novel long non-coding RNA linc-ZNF469-3 promotes lung metastasis through miR-574-5p-ZEB1 axis in triple negative breast cancer. Oncogene. 2018;37(34):4662\u201378. https:\/\/doi.org\/10.1038\/s41388-018-0293-1.","journal-title":"Oncogene"},{"issue":"23","key":"2846_CR121","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1038\/onc.2013.267","volume":"33","author":"C Soria-Valles","year":"2014","unstructured":"Soria-Valles C, et al. The anti-metastatic activity of collagenase-2 in breast cancer cells is mediated by a signaling pathway involving decorin and miR-21. Oncogene. 2014;33(23):3054\u201363. https:\/\/doi.org\/10.1038\/onc.2013.267.","journal-title":"Oncogene"},{"issue":"6","key":"2846_CR122","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1158\/0008-5472.CAN-19-1934","volume":"80","author":"I S\u00e1nchez-Gonz\u00e1lez","year":"2020","unstructured":"S\u00e1nchez-Gonz\u00e1lez I, et al. miR-149 suppresses breast cancer metastasis by blocking paracrine interactions with macrophages. Cancer Res. 2020;80(6):1330\u201341. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-1934.","journal-title":"Cancer Res"},{"issue":"3","key":"2846_CR123","first-page":"965","volume":"10","author":"M Yan","year":"2020","unstructured":"Yan M, et al. MicroRNA-590-3p inhibits invasion and metastasis in triple-negative breast cancer by targeting Slug. Am J Cancer Res. 2020;10(3):965\u201374.","journal-title":"Am J Cancer Res"},{"issue":"4","key":"2846_CR124","doi-asserted-by":"publisher","first-page":"4805","DOI":"10.3892\/ol.2017.6778","volume":"14","author":"X Zhang","year":"2017","unstructured":"Zhang X, Ma G, Liu J, Zhang Y. MicroRNA-182 promotes proliferation and metastasis by targeting FOXF2 in triple-negative breast cancer. Oncol Lett. 2017;14(4):4805\u201311. https:\/\/doi.org\/10.3892\/ol.2017.6778.","journal-title":"Oncol Lett"},{"issue":"11","key":"2846_CR125","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1158\/1541-7786.MCR-18-0284","volume":"16","author":"M Sang","year":"2018","unstructured":"Sang M, et al. Circular RNA ciRS-7 maintains metastatic phenotypes as a ceRNA of miR-1299 to target MMPs. Mol Cancer Res. 2018;16(11):1665\u201375. https:\/\/doi.org\/10.1158\/1541-7786.MCR-18-0284.","journal-title":"Mol Cancer Res"},{"key":"2846_CR126","doi-asserted-by":"publisher","first-page":"654672","DOI":"10.3389\/fonc.2021.654672","volume":"11","author":"J Zhang","year":"2021","unstructured":"Zhang J, et al. The miR-124-3p\/Neuropilin-1 axis contributes to the proliferation and metastasis of triple-negative breast cancer cells and Co-activates the TGF-\u03b2 pathway. Front Oncol. 2021;11:654672. https:\/\/doi.org\/10.3389\/fonc.2021.654672.","journal-title":"Front Oncol"},{"issue":"6346","key":"2846_CR127","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1126\/science.aai8515","volume":"357","author":"K Naxerova","year":"2017","unstructured":"Naxerova K, et al. Origins of lymphatic and distant metastases in human colorectal cancer. Science. 2017;357(6346):55\u201360. https:\/\/doi.org\/10.1126\/science.aai8515.","journal-title":"Science"},{"issue":"2","key":"2846_CR128","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/gcc.22422","volume":"56","author":"V Damiano","year":"2017","unstructured":"Damiano V, et al. \u201cEpigenetic silencing of miR-200c in breast cancer is associated with aggressiveness and is modulated by ZEB1.\u201d Genes Chromosom Cancer. 2017;56(2):147\u201358. https:\/\/doi.org\/10.1002\/gcc.22422.","journal-title":"Genes Chromosom Cancer"},{"issue":"2","key":"2846_CR129","doi-asserted-by":"publisher","first-page":"10126","DOI":"10.1080\/21655979.2021.2000741","volume":"12","author":"X Zeng","year":"2021","unstructured":"Zeng X, et al. MicroRNA-582-5p promotes triple-negative breast cancer invasion and metastasis by antagonizing CMTM8. Bioengineered. 2021;12(2):10126\u201335. https:\/\/doi.org\/10.1080\/21655979.2021.2000741.","journal-title":"Bioengineered"},{"key":"2846_CR130","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.3389\/fonc.2020.01371","volume":"10","author":"S-J Shen","year":"2020","unstructured":"Shen S-J, et al. MicroRNA-27b-3p promotes tumor progression and metastasis by inhibiting peroxisome proliferator-activated receptor gamma in triple-negative breast cancer. Front Oncol. 2020;10:1371. https:\/\/doi.org\/10.3389\/fonc.2020.01371.","journal-title":"Front Oncol"},{"issue":"10","key":"2846_CR131","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1093\/carcin\/bgu133","volume":"35","author":"B Humphries","year":"2014","unstructured":"Humphries B, et al. MicroRNA-200b targets protein kinase C\u03b1 and suppresses triple-negative breast cancer metastasis. Carcinogenesis. 2014;35(10):2254\u201363. https:\/\/doi.org\/10.1093\/carcin\/bgu133.","journal-title":"Carcinogenesis"},{"issue":"3","key":"2846_CR132","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.3892\/ol.2019.10548","volume":"18","author":"J Chu","year":"2019","unstructured":"Chu J. MicroRNA-589 serves as a tumor suppressor microRNA through directly targeting metastasis-associated protein 2 in breast cancer. Oncol Lett. 2019;18(3):2232\u20139. https:\/\/doi.org\/10.3892\/ol.2019.10548.","journal-title":"Oncol Lett"},{"issue":"7","key":"2846_CR133","doi-asserted-by":"publisher","first-page":"10819","DOI":"10.1002\/jcp.27906","volume":"234","author":"Z-D Lv","year":"2019","unstructured":"Lv Z-D, et al. miR-135b promotes proliferation and metastasis by targeting APC in triple-negative breast cancer. J Cell Physiol. 2019;234(7):10819\u201326. https:\/\/doi.org\/10.1002\/jcp.27906.","journal-title":"J Cell Physiol"},{"key":"2846_CR134","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.2147\/OTT.S161996","volume":"11","author":"W Tang","year":"2018","unstructured":"Tang W, et al. MicroRNA-150 suppresses triple-negative breast cancer metastasis through targeting HMGA2. Onco Targets Ther. 2018;11:2319\u201332. https:\/\/doi.org\/10.2147\/OTT.S161996.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"2846_CR135","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/bjc.2017.150","volume":"117","author":"L-L Chen","year":"2017","unstructured":"Chen L-L, Zhang Z-J, Yi Z-B, Li J-J. MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1. Br J Cancer. 2017;117(1):78\u201388. https:\/\/doi.org\/10.1038\/bjc.2017.150.","journal-title":"Br J Cancer"},{"issue":"2","key":"2846_CR136","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4048\/jbc.2014.17.2.143","volume":"17","author":"U Berber","year":"2014","unstructured":"Berber U, Yilmaz I, Narli G, Haholu A, Kucukodaci Z, Demirel D. miR-205 and miR-200c: predictive micro RNAs for lymph node metastasis in triple negative breast cancer. J Breast Cancer. 2014;17(2):143\u20138. https:\/\/doi.org\/10.4048\/jbc.2014.17.2.143.","journal-title":"J Breast Cancer"},{"issue":"1","key":"2846_CR137","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.canlet.2014.11.050","volume":"357","author":"P Liu","year":"2015","unstructured":"Liu P, et al. miR-26a suppresses tumour proliferation and metastasis by targeting metadherin in triple negative breast cancer. Cancer Lett. 2015;357(1):384\u201392. https:\/\/doi.org\/10.1016\/j.canlet.2014.11.050.","journal-title":"Cancer Lett"},{"issue":"1","key":"2846_CR138","doi-asserted-by":"publisher","first-page":"135","DOI":"10.7150\/jca.22181","volume":"9","author":"V Chernyy","year":"2018","unstructured":"Chernyy V, Pustylnyak V, Kozlov V, Gulyaeva L. Increased expression of miR-155 and miR-222 is associated with lymph node positive status. J Cancer. 2018;9(1):135\u201340. https:\/\/doi.org\/10.7150\/jca.22181.","journal-title":"J Cancer"},{"key":"2846_CR139","doi-asserted-by":"publisher","DOI":"10.3390\/ncrna6030029","author":"JS Wong","year":"2020","unstructured":"Wong JS, Cheah YK. Potential miRNAs for miRNA-Based Therapeutics in Breast Cancer. Non-Coding RNA. 2020. https:\/\/doi.org\/10.3390\/ncrna6030029.","journal-title":"Non-Coding RNA"},{"key":"2846_CR140","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.bbrc.2021.04.040","volume":"558","author":"T Zhang","year":"2021","unstructured":"Zhang T, Wu Y, Yang D, Wu C, Li H. Preparation, characterization, and in vitro tumor-suppressive effect of anti-miR-21-equipped RNA nanoparticles. Biochem Biophys Res Commun. 2021;558:107\u201313. https:\/\/doi.org\/10.1016\/j.bbrc.2021.04.040.","journal-title":"Biochem Biophys Res Commun"},{"key":"2846_CR141","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jconrel.2019.10.007","volume":"313","author":"SWL Lee","year":"2019","unstructured":"Lee SWL, et al. MicroRNA delivery through nanoparticles. J Control Release Off J Control Release Soc. 2019;313:80\u201395. https:\/\/doi.org\/10.1016\/j.jconrel.2019.10.007.","journal-title":"J Control Release Off J Control Release Soc"},{"issue":"12","key":"2846_CR142","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/mt.2012.201","volume":"20","author":"L Li","year":"2012","unstructured":"Li L, et al. Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasion. Mol Ther. 2012;20(12):2326\u201334. https:\/\/doi.org\/10.1038\/mt.2012.201.","journal-title":"Mol Ther"},{"key":"2846_CR143","doi-asserted-by":"publisher","DOI":"10.3390\/genes12081206","author":"MA Shadbad","year":"2021","unstructured":"Shadbad MA, et al. A systematic review on the therapeutic potentiality of pd-l1-inhibiting micrornas for triple-negative breast cancer: toward single-cell sequencing-guided biomimetic delivery. Genes (Basel). 2021. https:\/\/doi.org\/10.3390\/genes12081206.","journal-title":"Genes (Basel)"},{"issue":"1","key":"2846_CR144","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s11658-019-0168-7","volume":"24","author":"M Liu","year":"2019","unstructured":"Liu M, Gong C, Xu R, Chen Y, Wang X. MicroRNA-5195-3p enhances the chemosensitivity of triple-negative breast cancer to paclitaxel by downregulating EIF4A2. Cell Mol Biol Lett. 2019;24(1):47. https:\/\/doi.org\/10.1186\/s11658-019-0168-7.","journal-title":"Cell Mol Biol Lett"},{"issue":"11","key":"2846_CR145","first-page":"2201","volume":"20","author":"LY Sha","year":"2016","unstructured":"Sha LY, et al. MiR-18a upregulation decreases Dicer expression and confers paclitaxel resistance in triple negative breast cancer. Eur Rev Med Pharmacol Sci. 2016;20(11):2201\u20138.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2846_CR146","unstructured":"L. S. University, O. A. U. T. Hospital, U. of Chicago, N. University of Lagos, and U. of Ibadan, Eds., \u201cTreatment Response and microRNA Profiles in Triple Negative Breast Cancer Patients Receiving Standard Chemotherapy.\u201d Feb. 14, 2021. [Online]. https:\/\/clinicaltrials.gov\/study\/NCT04771871"},{"issue":"11","key":"2846_CR147","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1080\/03007995.2024.2416985","volume":"40","author":"NM Hamdy","year":"2024","unstructured":"Hamdy NM, et al. Advancements in current one-size-fits-all therapies compared to future treatment innovations for better improved chemotherapeutic outcomes: a step-toward personalized medicine. Curr Med Res Opin. 2024;40(11):1943\u201361. https:\/\/doi.org\/10.1080\/03007995.2024.2416985.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"2846_CR148","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s44316-025-00028-z","volume":"2","author":"KP Ameya","year":"2025","unstructured":"Ameya KP, Sekar D. Advances in paper-based biosensors for point-of-care miRNA detection. Biotechnol Sustain Mater. 2025;2(1):6. https:\/\/doi.org\/10.1186\/s44316-025-00028-z.","journal-title":"Biotechnol Sustain Mater"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02846-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02846-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02846-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T05:05:21Z","timestamp":1753938321000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02846-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,28]]},"references-count":148,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["2846"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02846-7","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,28]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"296"}}